Search Resources
Search Resources

Updated Resources

0 July 27, 2015

We’ve updated the resources for pharmacists by including a page with a list of training and CE opportunities for pharmacists. You can access the list here: http://rxpgx.com/resources/pharmacist-resources-2/training-opportunities This new resources will be updated as more CE opportunities are made available.

Posted in Uncategorized by Rachel Mills
0 June 19, 2015

We’ve updated the resource that includes a table of all medications with pharmacogenetic information in their drug label. All updates were made based on changes to a similar table maintained by the FDA. Changes include the additional of links to new CPIC guidelines for Celexa®(citalopram), Luvox® CR(fluvoxamine), Paxil®(paroxetine), Dilantin®(phenytoin), Elitek®(rasburicase), and Incivek®(telaprevir). See the entire table under the “Pharmacist Resources” tab or by clicking here.

Posted in Uncategorized by Rachel Mills
0 May 21, 2015

On May 5, 2015 the Duke Clinical Research Institute (DCRI) sponsored a lecture on Pharmacogenetics in Cardiovascular Disease. View the video here, or via the DCRI YouTube page where you can view other past lectures.

Posted in Uncategorized by Rachel Mills
0 May 19, 2015

A new clinical pharmacogenetics implementation consortium (CPIC) review and guideline have been published regarding pharmacogenetic testing and prescribing of the immunosuppressant drug tacrolimus. Published literature leading to this guideline has shown that extensive and intermediate CYP3A5 metabolizers have decreased concentrations of tacrolimus, suggesting that the starting dose should be increased 1.5 to 2 times the recommended dose. Therapeutic drug monitoring is also recommended to further guide dose adjustments. The review and guidelines can be viewed online via PharmGKB  or in the journal Clinical Pharmacology and Therapeutics (Birdwell et al. Clinical pharmacogenetics implementation consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing. Clin Pharmacol Ther 2015 doi: 10.1002/cpt.113)

Posted in Uncategorized by Rachel Mills